# EDGAR Filing Document

**Accession Number:** 0001659352
**File Stem:** 0001172661-23-000537
**Filing Date:** 2023-2
**Character Count:** 19580
**Document Hash:** fff96b885afa4a1b34c10ed48bfe623f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001172661-23-000537.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001172661-23-000537

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Codiak BioSciences, Inc.
- **CENTRAL INDEX KEY:** 0001659352
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91823
- **FILM NUMBER:** 23600070

**BUSINESS ADDRESS:**
- **STREET 1:** 35 CAMBRIDGEPARK DRIVE
- **STREET 2:** SUITE 500
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
- **BUSINESS PHONE:** 617-949-4100

**MAIL ADDRESS:**
- **STREET 1:** 35 CAMBRIDGEPARK DRIVE
- **STREET 2:** SUITE 500
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Codiak Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20151125
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Laurion Capital Management LP
- **CENTRAL INDEX KEY:** 0001390202
- **IRS NUMBER:** 562504425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** SUITE 2000
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-938-6325

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** SUITE 2000
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION<br> Washington, DC 20549**

**SCHEDULE 13G**

<br> **Under the Securities Exchange Act of 1934**

**(Amendment No.**)\*

**Codiak Biosciences, Inc.**

---

| |
|:---|
| &nbsp;&nbsp;(Name of Issuer) |
| &nbsp;&nbsp; <br> **Common Stock, par value $0.0001 per share**<br>|
| &nbsp;&nbsp;(Title of Class of Securities) |
| &nbsp;&nbsp;<br> **192010106**<br>|
| &nbsp;&nbsp;(CUSIP Number) |
| &nbsp;&nbsp; **December 31, 2022** |
| &nbsp;&nbsp;(Date of Event Which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

⌧ Rule 13d-1(b)

□ Rule 13d-1(c)

□ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 2 of 9 Pages** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | NAME OF REPORTING PERSONS<br>Laurion Capital Management LP | NAME OF REPORTING PERSONS<br>Laurion Capital Management LP | NAME OF REPORTING PERSONS<br>Laurion Capital Management LP | NAME OF REPORTING PERSONS<br>Laurion Capital Management LP |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ |  |
| 3 | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION<br> Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br> Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br> Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br> Delaware |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | SOLE VOTING POWER | SOLE VOTING POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | SHARED VOTING POWER<br>2,013,300 | SHARED VOTING POWER<br>2,013,300 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | SOLE DISPOSITIVE POWER | SOLE DISPOSITIVE POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | SHARED DISPOSITIVE POWER<br>2,013,300 | SHARED DISPOSITIVE POWER<br>2,013,300 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% |
| 12 | TYPE OF REPORTING PERSON <br>PN, IA | TYPE OF REPORTING PERSON <br>PN, IA | TYPE OF REPORTING PERSON <br>PN, IA | TYPE OF REPORTING PERSON <br>PN, IA |

---

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 3 of 9 Pages** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | NAME OF REPORTING PERSONS<br>Benjamin Alexander Smith | NAME OF REPORTING PERSONS<br>Benjamin Alexander Smith | NAME OF REPORTING PERSONS<br>Benjamin Alexander Smith | NAME OF REPORTING PERSONS<br>Benjamin Alexander Smith |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ |  |
| 3 | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United States |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | SOLE VOTING POWER | SOLE VOTING POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | SHARED VOTING POWER<br>2,013,300 | SHARED VOTING POWER<br>2,013,300 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | SOLE DISPOSITIVE POWER | SOLE DISPOSITIVE POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | SHARED DISPOSITIVE POWER<br>2,013,300 | SHARED DISPOSITIVE POWER<br>2,013,300 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% |
| 12 | TYPE OF REPORTING PERSON <br>IN | TYPE OF REPORTING PERSON <br>IN | TYPE OF REPORTING PERSON <br>IN | TYPE OF REPORTING PERSON <br>IN |

---

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 4 of 9 Pages** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | NAME OF REPORTING PERSONS<br>Janaka Sheehan Maduraperuma | NAME OF REPORTING PERSONS<br>Janaka Sheehan Maduraperuma | NAME OF REPORTING PERSONS<br>Janaka Sheehan Maduraperuma | NAME OF REPORTING PERSONS<br>Janaka Sheehan Maduraperuma |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ |  |
| 3 | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United Kingdom | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United Kingdom | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United Kingdom | CITIZENSHIP OR PLACE OF ORGANIZATION<br> United Kingdom |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | SOLE VOTING POWER | SOLE VOTING POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | SHARED VOTING POWER<br>2,013,300 | SHARED VOTING POWER<br>2,013,300 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | SOLE DISPOSITIVE POWER | SOLE DISPOSITIVE POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | SHARED DISPOSITIVE POWER<br>2,013,300 | SHARED DISPOSITIVE POWER<br>2,013,300 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,013,300 |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>5.5% |
| 12 | TYPE OF REPORTING PERSON <br>IN | TYPE OF REPORTING PERSON <br>IN | TYPE OF REPORTING PERSON <br>IN | TYPE OF REPORTING PERSON <br>IN |

---

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 5 of 9 Pages** |

---

**Item 1.** **(a) Name of Issuer**

Codiak Biosciences, Inc.

**(b) Address of Issuer's Principal Executive Offices**

35 Cambridgepark Drive, Suite 500

Cambridge, MA 02140

**Item 2.** **(a) Name of Person Filing**

This statement is filed by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Laurion Capital Management LP ("<u>Laurion Capital</u>"), a Delaware limited partnership, and the investment adviser to certain funds and accounts (the "<u>Laurion Funds</u>"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Laurion Funds;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Mr. Benjamin Alexander Smith ("<u>Mr. Smith</u>"), the co-managing member of Laurion Capital GP LLC, the general partner of Laurion Capital, with respect to the shares of Common Stock directly held by the Laurion Funds.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Mr. Janaka Sheehan Maduraperuma ("<u>Mr. Maduraperuma</u>"), the co-managing member of Laurion Capital GP LLC, the general partner of Laurion Capital, with respect to the shares of Common Stock directly held by the Laurion Funds.

The foregoing persons are hereinafter sometimes collectively referred to as the "<u>Reporting Persons</u>."

The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

**(b) Address of Principal Business Office, or, if none, Residence**

The address of the business office of each of the Reporting Persons is 360 Madison Avenue, Suite 1900, New York, NY 10017.

**(c) Citizenship**

Laurion Capital is a Delaware limited partnership. Mr. Smith is a citizen of the United States. Mr. Maduraperuma is a citizen of the United Kingdom.

**(d) Title of Class of Securities**

Common Stock, par value $0.0001 per share (the "Common Stock")

**(e) CUSIP No.:**

192010106

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 6 of 9 Pages** |

---

(a) ◻ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ◻ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ◻ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) □ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ⌧ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) ◻ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g) ⌧ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h) ◻ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ◻ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
 Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ◻ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k) ◻ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
 please specify the type of institution: <u> </u> 

Not Applicable

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 7 of 9 Pages** |

---

**Item 4. Ownership**

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

The percentages set forth herein are calculated based upon 36,829,626 shares of Common Stock outstanding as of October 27, 2022 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on November 3, 2022.

**Item 5. Ownership of Five Percent or Less of a Class**

Not Applicable.

**Item 6. Ownership of More Than Five Percent on Behalf of Another Person**

See Item 2. The Laurion Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Laurion Capital Master Fund Ltd., a Laurion Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares of Common Stock.

**Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

**Item 10. Certifications**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 8 of 9 Pages** |

---

**<u>SIGNATURE</u>**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 8, 2023

---

| | | |
|:---|:---|:---|
| By: | /s/ Jason Riesel | /s/ Jason Riesel |
|  | Name: | Jason Riesel |
|  | Title: | General Counsel & CCO |
| By: | /s/ Benjamin Alexander Smith | /s/ Benjamin Alexander Smith |
|  | Name: | Benjamin Alexander Smith |
| By: | /s/ Janaka Sheehan Maduraperuma | /s/ Janaka Sheehan Maduraperuma |
|  | Name: | Janaka Sheehan Maduraperuma |

---

---

| | | |
|:---|:---|:---|
| **CUSIP No. 192010106** | **SCHEDULE 13G** | &nbsp;&nbsp;&nbsp; **Page 9 of 9 Pages** |

---

**<u>JOINT FILING AGREEMENT</u>**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the shares of Common Stock of Research Alliance Corp. II, and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 8, 2023.

---

| | | |
|:---|:---|:---|
| By: | /s/ Jason Riesel | /s/ Jason Riesel |
|  | Name: | Jason Riesel |
|  | Title: | General Counsel & CCO |
| By: | /s/ Benjamin Alexander Smith | /s/ Benjamin Alexander Smith |
|  | Name: | Benjamin Alexander Smith |
| By: | /s/ Janaka Sheehan Maduraperuma | /s/ Janaka Sheehan Maduraperuma |
|  | Name: | Janaka Sheehan Maduraperuma |

---